01/06/2026
On Dec. 9, our Johns Hopkins Hospital team performed the Baltimore/Washington region's first commercial transurethral ultrasound ablation (TULSA) procedure — a minimally invasive, MRI-guided treatment for prostate cancer and benign prostatic hyperplasia (BPH). Johns Hopkins is now the first and only health system in the Baltimore/Washington region to offer TULSA as a treatment option. Learn more about our comprehensive prostate cancer treatment options at the Brady Urological Institute: https://www.hopkinsmedicine.org/brady-urology-institute/conditions-and-treatments/prostate-cancer